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Abstract
Objectives—The aim of the study was to determine whether combination antiretroviral therapy
(cART) with high central nervous system penetration-effectiveness (CPE) rank (neurocART) is
associated with increased survival benefit compared with non-neurocART.
Methods—Prospective data were examined for HIV-positive patients in the Asia Pacific HIV
Observational Database who had commenced cART. CPE rank was calculated using the 2010
rankings process. NeurocART status was assigned to regimens with a CPE rank of 8 or more.
Survival was analysed using Cox proportional hazards models with covariates updated at changes
in cART regimen and with deaths up to 90 days after regimen cessation attributed to that regimen.
Sensitivity analyses were conducted to examine the robustness of analysis assumptions.
Results—Among 5882 patients, 308 deaths occurred. The hazard ratio (HR) for neurocART use
was 0.89 (P = 0.35) when data were stratified by cohort and adjusted for age, mode of HIV
exposure, hepatitis B virus coinfection, AIDS-defining illness, CD4 count (cells/μL) and regimen
count. Sensitivity analyses showed similar nonsignificant results. We also examined a composite
endpoint of AIDS-defining illness or death (HR = 0.93; P = 0.61), baseline regimen as neurocART
(HR = 0.95; P = 0.69), CPE category (P = 0.71) and prior neurocART duration (P = 0.16). No
association between CD4 cell count and neurocART use was observed (P = 0.52).
Conclusions—Our findings do not show a significant overall survival benefit associated with
neurocART compared with cART. The potential benefit associated with neurocART in terms of
prevention of neurocognitive impairment did not translate into an improvement in overall survival
in this population. These findings were limited by the low incidence of associated mortality.
Further studies and more extensive data are needed to address these limitations.
© 2011 British HIV Association
Correspondence: Mr Hamish McManus, University of New South Wales, Cliffbrook Campus, 45 Beach Street, Coogee, NSW 2034,
Australia. Tel: + 61 2 9385 0994; fax: + 612 9385 0940; hmcmanus@nchecr.unsw.edu.au.
NIH Public Access
Author Manuscript
HIV Med. Author manuscript; available in PMC 2012 April 9.
Published in final edited form as:
HIV Med. 2011 November ; 12(10): 610–619. doi:10.1111/j.1468-1293.2011.00938.x.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
antiretroviral therapy; central nervous system penetration-effectiveness score; combination
antiretroviral therapy; HIV; neurocART
Introduction
In a recent study by Patel et al. of over 2272 HIV-infected children, the use of combination
antiretroviral therapy (cART) regimens with good central nervous system (CNS) penetration
(neurocART) was associated with a significant overall survival benefit (70% risk reduction)
compared with use of non-neurocART [1]. In the same study, the use of neurocART was not
significantly associated with a reduced incidence of HIV encephalopathy compared with the
use of non-neurocART. It is possible that the improved overall survival conferred by
neurocART in this paediatric cohort may have been related to better treatment of milder
(and probably undiagnosed) HIV-associated neurocognitive impairment (NCI) [2]. In
general HIV-positive populations, even mild NCI can affect adherence [3,4], implying a
resultant limitation of antiretroviral (ARV) options and an increase in HIV-related
complications. In such instances, NCI can be associated with death without the mechanism
being through dementia. Further, it is plausible that neurocART regimens afforded improved
survival through their being more efficacious at achieving and maintaining an undetectable
HIV viral load. However, this association was not evaluable in the study of Patel et al. [1]
and neurocART has not been associated with greater suppression of plasma HIV viral load
in other studies [5].
In Western countries, HIV-associated dementia (HAD) occurs in approximately 15–20% of
patients with advanced, untreated HIV infection. In the CASCADE cohort, where patients
are recruited from Europe, Canada and Australia, the incidence of HAD was 6.49 per 1000
person-years in the pre-cART era and had fallen to 0.66 by 2003–2006 [6]. In the Asia
Pacific region, 12% of HIV-positive out-patients across eight countries had moderate-to-
severe NCI compatible with HAD [7]. The prevalence of milder HIV-associated NCI in the
Asia and Pacific region is unknown but in a study from India, where HIV-1 clade C
predominates, 60% of patients had mild-to-moderate HIV-related neurocognitive deficits
[8]. Similarly, a study from Thailand noted a sizeable frequency of mild NCI and the rare
occurrence of HAD [9].
HAD per se is associated with an increased risk of mortality [10–13], and the reasons for
this are probably multifactorial. The optimal antiretroviral treatment for HAD remains
controversial but there is evidence to suggest that use of cART regimens with good CNS
penetration is superior to the use of regimens with poor CNS penetration [2,14–16].
Recently, Letendre et al. have assigned antiretroviral agents individual CNS penetration-
effectiveness (CPE) ranks [16,17]. Patients using antiretroviral regimens with a total CPE
rank of 8 or more are significantly less likely to have a detectable cerebrospinal fluid HIV
viral load than patients using antiretroviral regimens with a total CPE rank below this
threshold [17].
The evidence of a strong survival benefit associated with neurocART [1] requires further
investigation in a general context regardless of the posited mechanism for survival. Because
the reasons for the associated survival benefit are not clear, and because survival may be
attributable to the treatment of mild and undiagnosed NCI in particular, the use of NCI as an
endpoint rather than survival may underestimate neurocART effects. Further, the beneficial
effects of using antiretroviral regimens with high CPE on overall survival in HIV-infected
adults has not been evaluated; hence we undertook this study using a combined analysis
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from the Australian HIV Observational Database (AHOD) and the TREAT Asia HIV
Observational Database (TAHOD).
Methods
Study population
AHOD and TAHOD are observational clinical cohort studies of patients with HIV infection
in Australia and countries in Asia and the Pacific region, respectively. As part of the
International Epidemiologic Databases to Evaluate AIDS initiative, these databases are
combined to form the Asia-Pacific HIV Observational Database (APHOD). APHOD utilizes
methodology that has been described in detail elsewhere [18,19].
In AHOD, data are collected from 27 clinical sites throughout Australia, including hospitals,
sexual health clinics and general medical practices. Prospective data collection commenced
in 1999, with retrospective data provided where available. Written, informed consent is
obtained from all patients recruited to AHOD at the time of enrolment. In TAHOD, data are
collected from 17 clinical sites in Asia and the Pacific region. Prospective data collection for
TAHOD commenced in 2003, with retrospective data provided where available. Written
consent was not a requirement of sites in TAHOD unless required by the site's local ethics
committee, because data are collected in an anonymous form. Ethics approval for APHOD
was obtained from the University of New South Wales, Sydney, Australia, and all other
relevant institutional review boards. All APHOD study procedures were developed in
accordance with the revised 1975 Helsinki Declaration.
Data for APHOD are transferred electronically to the National Centre in HIV Epidemiology
and Clinical Research (NCHECR) every March and September and include the same set of
core variables. All data are subject to standardized quality control procedures. We included
all patients recruited to APHOD by 31 March 2009, who commenced cART (three or more
antiretroviral drugs in combination) after 1 January 1997 and had at least one follow-up
visit. All data were analysed centrally at the NCHECR.
Definitions and outcome
Initial baseline was the later date of commencement of cART (defined as the use of three or
more antiretrovirals) and enrolment in APHOD. The primary endpoint was mortality,
including mortality up to 90 days after cessation of cART. Periods off cART of duration <90
days were considered to be continued cART based on intention-to-treat principles. Periods
off cART with a duration of >90 days were omitted from the primary analysis. A new cART
regimen was defined as a regimen created from an existing regimen by the addition of one
or more new antiretrovirals, or by the replacement of one or more antiretrovirals in the
existing regimen with one or more new antiretrovirals. NeurocART status was assigned to
those regimens with a CPE rank of 8 or more, with the CPE rank calculated using the 2010
rankings process [17]. CD4 cell counts and viral loads were taken as the latest measurement
from up to 90 days prior to regimen commencement. HIV viral load measurements of ≤400
copies/mL were defined as undetectable because more sensitive assays were not uniformly
available for all observations. Coinfection with hepatitis B virus (HBV) or hepatitis C virus
(HCV) was defined as the detection of HBV surface antigen or HCV antibody, respectively.
A secondary composite endpoint of AIDS or mortality within 90 days of cessation of
treatment was also investigated.
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Statistical analysis
Follow-up was calculated from the start date of each new cART regimen (or the date of
cohort enrolment if later), until cessation of that cART regimen. Loss to follow-up was
defined as no clinic visit in the 12 months prior to 31 March 2009 (cohort censoring date).
Patients lost to follow-up were censored at their last clinic visit. We used an intention-to-
continue treatment approach and ignored any changes to, or interruptions or termination of,
treatment after baseline.
For each new cART regimen we created a new set of baseline covariates and assessed the
risk of death on that cART regimen adjusted for those baseline covariates. Variables updated
at change in cART regimen were neurocART status, CD4 count (<50, 50–99, 100–199,
200–349 and ≥350 cells/μL, or missing), HIV viral load (≤400 or >4400 HIV-1 RNA
copies/mL, or missing), prior AIDS-defining illness (ADI), cART regimen count (first,
second, third, fourth or more), months of prior neurocART exposure (never, or 1–9, 10–18
or >18 months), and months of prior cART (not neurocART) exposure (never, or 1–18 or
>418 months). Additional variables examined were age (<30, 30–39, 40–49 or ≥50 years),
sex, mode of HIV exposure [men who have sex with men (MSM), heterosexual, injecting
drug use (IDU), other or missing], HCV coinfection, HBV coinfection, and neurocART type
prior to entry (naïve, cART and not neurocART, or neurocART). We also analysed the
incidence of HAD. As there is some evidence that progressive multifocal
leucoencephalopathy (PML) may respond better to neurocART than non-neurocART [20],
PML data were also analysed. We did not have data on patients' CD4 cell count nadirs. An
administrative censoring date of 31 March 2009 was used. Univariate Cox proportional
hazards models were developed for all variables. Multivariate analysis of survival and
neurocART status was conducted using Cox proportional hazards models with covariates
selected using backward stepwise selection and with forced inclusion of neurocART. All
primary analyses were stratified by cohort. Covariates were excluded if there appeared to be
collinearity problems. We accounted for the multiple regimens per patient by applying
robust standard error estimation to allow for intragroup correlation. Missing data were
included as a separate category in all analyses.
The following sensitivity analyses were conducted using multivariate Cox proportional
hazards models: separate analyses were conducted for each cohort; for each change in
neurocART status a new set of baseline covariates was created; off-cART periods of >90
days were included; all deaths following treatment cessation were excluded; all periods of
mono/dual therapy exposures were excluded; and all records with missing CD4 cell counts
or viral loads were excluded. A sensitivity analysis was also conducted using Poisson
regression as opposed to a Cox regression.
Secondary analyses were conducted as follows: neuro-cART status as a predictor of `ADI or
death' within 90 days of cessation of treatment was examined; neurocART as first cART
(compared with non-neurocART as first cART) was investigated as a predictor of mortality;
CPE score categorized as a four-point variable by quartile (≤6, 7, 8 and ≥9) was investigated
as a predictor of mortality; cumulative duration of neurocART use in months prior to the
current regimen was also investigated as a predictor of mortality. This was examined as a
categorical predictor (never, or 1–29, 10–18 or ≥19 months) with a broad upper category (≥
19 months) to avoid fitting to patients who survived and had extended follow-up, thereby
reducing the potential for bias in survival estimates. This model was compared with the
model used in the primary analysis using the Akaike information criterion. In these analyses,
covariates used were as for the primary analysis.
Finally, we also assessed CD4 cell count responses according to neurocART status. Log
CD4 cell count was analysed using repeated measures regression, with generalized
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estimating equations (GEE) methodology, and assumed exchangeable variance structure
(but robust calculated variances). CD4 cell counts were recorded for up to 540 days at each
90 days of regimen duration using the closest measurement (taken <90 days before or <30
days after). Additional covariates were included in this analysis: baseline CD4 count (<50,
50–99, 100–199, 200–349 or ≥350 cells/μL or missing), year of cART commencement
(1997–1999, 2000–2002 or ≥2003) and time since first cART (≤270, 271–540, 541–810 or
>810 days).
Data were analysed using STATA version 10 (Stata Corporation, College Station, TX,
USA).
Results
Patient characteristics
Demographic and clinical characteristics by cohort are summarized in Table 1. A total of
5882 patients were included in these analyses (2384 from AHOD and 3498 from TAHOD),
contributing 22117 patient-years of follow up. A total of 308 (5%) of patients died during
follow-up (195 in AHOD and 113 in TAHOD), with an observed incidence rate of 12.3
deaths per 1000 person-years of follow up [95% confidence interval (CI) 11.0–13.8]. The
median age was 43 years [standard deviation (SD) 9.8 years] in AHOD and 38 years (SD 9.6
years) in TAHOD. The majority of patients were male; 94% of patients were male in AHOD
compared with 71% of patients in TAHOD. The main exposure category in AHOD was
homosexual contact (78%) compared with heterosexual contact (68%) in TAHOD.
Low incidences of HAD were observed: 36 (2%) and five deaths in AHOD and 14 (<1%)
and one death in TAHOD. Similarly, low incidences of PML were observed; two (<1%) and
no deaths in AHOD and 10 (<1%) and two deaths in TAHOD (Table 1).
The median observed CPE based on treatment time was 8 [interquartile range (IQR) 7–9].
Prior neurocART had been received by 1267 AHOD patients (53%) compared with 2454
TAHOD patients (70%). The average prior cumulative neurocART duration in AHOD was
13 months (SD 20.7 months) compared with 10 months (SD 15.4 months) in TAHOD. Of
the patients in AHOD, 1129 (47%) had neurocART as the first cART whereas in TAHOD,
2630 (75%) had neurocART as the first cART.
NeurocART use
There was no significant difference in the risk of mortality between neurocART and non-
neurocART groups for either the univariate or the multivariate models (Table 2). The
unadjusted hazard ratio (HR) associated with neurocART use was 0.87 (95% CI 0.68–1.12).
Variables associated with survival in univariate models were age at entry, HIV exposure
category, HBV coinfection, HCV coinfection, ADI, CD4 cell count, HIV viral load, prior
treatment, regimen count and duration of prior cART (not neurocART) exposure.
Covariates retained in the final multivariate model were age, HIV exposure category, HBV
coinfection, ADI, CD4 cell count and regimen. In this model the adjusted HR associated
with neurocART use was 0.89 (95% CI 0.69, 1.14) (Table 2). Covariates associated with
increased mortality in this model were age >50 years compared with age <30 years (HR
2.47; 95% CI 1.53–3.99), exposure from IDU compared with MSM (HR 2.01; 95% CI 1.33–
3.05), lower CD4 cell count and regimen fourth or more compared with first (HR 1.57; 95%
CI 1.13–2.17). Analyses by cohort showed no significant difference in the risk of mortality
between neurocART and non-neurocART groups; the adjusted HR associated with
neurocART use was 0.81 (95% CI 0.59–1.12) for AHOD and 0.92 (95% CI 0.59–1.43) for
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TAHOD. All other sensitivity analyses showed similar, nonsignificant differences in risk of
mortality for the neurocART and non-neurocART groups (Table 3).
There was no significant difference in the risk of AIDS or death between the neurocART
and non-neurocART groups for either of the univariate or multivariate models (Table 4).
The adjusted HR associated with neurocART use was 0.93 (95% CI 0.71–1.23). Similarly,
there was no significant difference in the risk of mortality between the group with
neurocART as the first cART (neurocART-first cART) and the group with non-neurocART
as the first cART (non-neurocART-first cART) for either of the univariate or multivariate
models (Table 4). The adjusted HR associated with neurocART-first cART was 0.91 (95%
CI 0.70–1.18). CPE as a four-point variable showed no significant association with risk of
mortality (P=0.71) (Table 4) for all categories of CPE. Also, there was no significant
difference in mortality associated with duration of prior neurocART use when used as a
primary independent predictor and adjusted for other covariates (P=0.16) (Table 4).
Regimen count was omitted from this analysis because of confounding. This model was less
successful than the model used in the primary analysis in describing overall mortality with
regard to numbers of covariate levels (Akaike information criterion 4183.7 compared with
4180.4).
No association between CD4 cell count and neurocART was observed (P=0.52) using a
GEE model adjusted for age, HIV exposure category, ADI, CD4 cell count at baseline, HIV
viral load, HBV coinfection, HCV coinfection, age, regimen count, year of first cART, time
since first cART and regimen duration as covariates (Table 4). In this model, a
nonsignificant increase in CD4 cell count of 1% (95% CI −2 to 4%) was observed per each
3 months of duration of neurocART regimens compared with non-neurocART regimens and
when adjusted for other covariates.
Discussion
In this analysis using data from APHOD, neurocART was not significantly associated with a
reduction in survival for HIV-positive patients, and this finding was consistently obtained
across a range of sensitivity analyses. Similarly, a nonsignificant association was observed
when the first incidence of ADI was incorporated as an endpoint, and no association was
found between neurocART use compared with cART use and CD4 cell count. At least in
APHOD, a potential benefit associated with neurocART use is not evident in overall
population survival.
The use of neurocART has been shown to improve survival after diagnosis of HIV
encephalopathy in perinatally infected children and adolescents [1], but survival effects are
less clear in general HIV-positive populations [21]. Our analysis does not confirm the
association of neurocART use and improved survival in a broader population of HIV-
infected adults, with our findings being robust to changes in model assumptions. Further, the
independent associations between other population and treatment characteristics and
survival in our study were consistent with other findings [18,19,22–24]: higher CD4 cell
count was strongly associated with reduced mortality, while increased HIV viral load,
increased age, certain modes of exposure (IDU and `other'), hepatitis coinfection, ADI and
more extensive treatment history (higher regimen count) were associated with increased
mortality. In the multivariate analysis, it was found that higher CD4 cell count, increased
age, HBV coinfection, ADI and more extensive treatment history (higher regimen count)
were strongly associated with survival after adjustment for other covariates. In terms of
survival prediction, neurocART was not very important to the models in comparison with
these covariates.
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We did not directly examine NCI-associated mortality, although an important rationale for
this study was the possible improvement in survival attributable to the beneficial effect of
neurocART on mild, and possibly undiagnosed and unmeasured, NCI [1]. Although
previous studies have demonstrated a sizeable frequency of mild NCI in certain populations
[8,9], we do not have comprehensive data on the incidence of mild NCI-associated mortality
in APHOD. To our knowledge, there is no strong existing evidence of survival attributable
to the beneficial effects of neurocART on mild NCI. A recent paper by Smurzynski et al.
[25] showed an adjusted association between increases in CPE score and neuropsychological
test scores when accounting for an interaction with the number of ARVs per regimen. While
Patel et al. did not find a significant association between CNS penetration and the incidence
of HIV encephalopathy, they did observe a significant survival benefit associated with CNS
penetration in HIV encephalopathy cases [1]. In contrast, while Garvey et al. did not observe
a significant adjusted association between CPE score and CNS opportunistic diseases, they
noted that the lowest and highest CPE scores were associated with increased mortality [21],
but suggested that this was a consequence of clinical status affecting prescribing practice.
Overall, our findings do not demonstrate the posited association between neurocART-
reduced NCI and improved survival in APHOD.
Our findings, which describe prospective data for the period 1999–2009, can be contrasted
with those of a recent study by Lanoy et al. [20], where all-cause mortality in neuroAIDS
diagnoses was associated with CPE score for each of the periods 1992–1995 and 1996–1998
but not for 1999–2004. In that study, the authors attributed the lack of an associated effect in
the period 1999–2004 to improved control of plasma viral load (which was not adjusted for
in initial models) by cART regimens in general. In the same study, a secondary analysis for
the period 1997–2004 showed no change in survival associated with CPE score after
including plasma HIV RNA as a covariate. While our results reflect a lack of a differentiable
survival effect of neurocART use in the later cART period for all HIV-positive patients, they
also suggest that plasma viral load adds little extra descriptive power after the inclusion of
CD4 cell count as a covariate in multivariate models when examining neurocART survival
outcomes. Similarly, while Patel et al. were unable to adjust for viral load in their primary
analysis, sensitivity analyses suggested that measured CNS effects were not confounded by
the omission of this covariate [1]. In this regard, temporal changes in the measured CPE
effect as observed by Lanoy et al. are not necessarily reflected by measured HIV RNA
suppression in these analyses, at least when also adjusting for CD4 cell counts.
Nevertheless, broader changes in therapy, including general increases in cART CPE levels
and potency, may reduce the effectiveness of CPE as a measure of neuroAIDS treatment,
and wider changes in therapy should be considered in association with CPE measurements
to describe the effectiveness of treatments of neuroAIDS.
Of note is the fact that in our study we used the 2010 CPE ranking approach, as presented by
Letendre et al. [17]. While this approach has not been validated at the time of submission,
we have found analysis results to be qualitatively similar to those obtained using the 2008
approach [16] (data not shown). There are acknowledged weaknesses with the CPE scoring
system, including scarce information on ARV CNS penetration and pharmacodynamics,
including possible insensitivity to drug–drug interactions, the role of blood–brain barrier
permeability in CNS drug penetration and the possible effects of ageing. However, the CPE
scoring system represents a practical tool with which to assess CNS effectiveness of cART
regimens and has been associated with strong measured improvement in overall survival in
one study [1]. As stated, a posited reason for this is that treatment of mild undiagnosed NCI
with neurocART improves overall survival, although we were not able to evaluate this in our
analysis. Furthermore, we were not able to evaluate the relationship between use of
neurocART and cerebrospinal fluid HIV viral load results.
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In APHOD, HAD and PML events are too rare to be used as statistical endpoints and
detailed data on other neurological events are not collected; however, we looked at broader
outcomes for neurocART use. The composite endpoint of `ADI or death' showed a weaker
association, suggesting that neurocART use does not reduce the incidence of ADI compared
with cART. Also of note is the finding that neurocART use was not strongly associated with
changes in CD4 cell count compared with cART use. These findings do not demonstrate any
additional benefit associated with neurocART use compared with non-neurocART use.
We also examined survival attributable to neurocART across different stages of treatment:
for baseline neuro-cART, subsequent neurocART, and cumulative duration of neurocART.
We observed a nonsignificant association between neurocART as the first cART and
survival, consistent with the findings of Garvey et al. [21], where baseline CPE category
was categorized as a four-level variable. In the same study, Garvey et al. found that the
lowest and highest categories of the latest CPE were associated with increased mortality in
multivariate models; however, we did not find an equivalent association in APHOD. We
also found that models using the latest neurocART showed a stronger, but still
nonsignificant, association with survival than equivalent four-level CPE models. Finally, we
observed no association between survival and duration of neurocART use when data were
adjusted for other patient characteristics. Overall, we were unable to demonstrate a
difference in survival associated with neurocART compared with non-neurocART.
There are several limitations to this study. Firstly, our study may have been underpowered to
detect a significant association between CPE score and overall survival. Sample size
calculations estimate that we would have needed over 1000 events to detect a significant
improvement in survival of<15%. The likely low incidence of death associated with NCI
further limits the power of analysis. In APHOD, the low incidence of HAD precluded it
from being analysed directly, and limited data are collected on other NCI outcomes.
Although APHOD comprises relatively large multisite cohorts with good follow-up, these
results flag the need for more extensive data for examination of neuro-cART outcomes
including associated mortality. In particular, examination of mild CNS events might increase
the sensitivity of analyses to general neurocART outcomes including associated mortality,
subject to available data and the constraints this places on the power of analyses. Although
TAPHOD does not collect these data in any standardized fashion, we are not aware of any
other cohorts that do so. In this regard, the routine screening for HIV-associated
neurocognitive disorders in relevant cohorts should be considered. Similarly, although
previous studies have identified clade-specific differences in HIV neurotoxicity [26], our
analysis did not specifically adjust for this. Differences in neurotoxicity by clade may
potentially limit the general application of CPE as used in this analysis, and the inclusion of
clade as a covariate to examine this should be considered in future analyses. Other
limitations include the enrolment of patients in APHOD after the initiation of cART, and the
enrolment of patients with mono/dual therapy experience prior to starting cART. To address
these concerns, prior treatment experience was factored into analyses including prior
treatment type, neurocART-first cART, regimen count and neurocART exposure. Of these
covariates, only higher regimen counts (≥4 regimens) were found to contribute significantly
to multivariate models.
In summary, our findings do not show a significant overall survival benefit associated with
neurocART compared with cART in a population of HIV-positive adult patients (APHOD).
In particular, the potential benefit associated with neurocART in terms of prevention of
neurocognitive impairment did not translate into an improvement in overall survival in this
population. These findings were limited by the likely low incidence of NCI-associated
mortality. Further studies and more extensive data are needed to address these limitations.
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Table 1
Demographic and clinical characteristics
AHOD TAHOD
Patients Deaths Patients Deaths
Total [n (%)]
Age at entry (years) n (%) 2384 (100) 195 (100) 3498 (100) 113 (100)
 Mean (SD) 43 (9.8) 38 (9.6)
 <30 years 148 (6) 6 (3) 602 (17) 17 (15)
 30–39 years 859 (36) 64 (33) 1641 (47) 37 (33)
 40–49 years 829 (35) 61 (31) 860 (25) 26 (23)
 ≥ 50 years 548 (23) 64 (33) 395 (11) 33 (29)
Gender [n (%)]
 Male 2240 (94) 185 (95) 2500 (71) 86 (76)
 Female 144 (6) 10 (5) 998 (29) 27 (24)
HIV exposure [n (%)]
 MSM 1854 (78) 143 (73) 651 (19) 8 (7)
 HET 221 (9) 10 (5) 2370 (68) 82 (73)
 IDU 147 (6) 21 (11) 169 (5) 10 (9)
 Other 138 (6) 18 (9) 256 (7) 12 (11)
 Missing 24 (1) 3 (2) 52 (1) 1 (1)
HBV coinfection [n (%)]
 Negative 1882 (79) 151 (77) 2085 (60) 59 (52)
 Positive 125 (5) 19 (10) 244 (7) 8 (7)
 Missing 377 (16) 25 (13) 1169 (33) 46 (41)
HCV coinfection [n (%)]
 Negative 1843 (77) 140 (72) 1856 (53) 51 (45)
 Positive 263 (11) 34 (17) 232 (7) 11 (10)
 Missing 278 (12) 21 (11) 1410 (40) 51 (45)
HAD ever [n (%)]
 No 2348 (98) 190 (97) 3484 (100) 112 (99)
 Yes 36 (2) 5 (3) 14 (0) 1 (0)
Progressive multifocal leucoencephalopathy [n (%)]
 No 2382 (100) 195 (100) 3488 (100) 111 (98)
 Yes 2 (0) 0 (0) 10 (0) 2 (2)
AIDS at entry [n (%)]
 No 1901 (80) 136 (70) 1754 (50) 34 (30)
 Yes 483 (20) 59 (30) 1744 (50) 79 (70)
CD4 count at entry (cells/|μL) n (%)
 Mean (SD) 460 (282.4) 274 (211.4)
 <50 cells/μL 80 (3) 32 (16) 373 (11) 31 (27)
 50–99 cells/μL 67 (3) 8 (4) 279 (8) 23 (20)
 100–199 cells/μL 249 (10) 31 (16) 650 (19) 23 (20)
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AHOD TAHOD
Patients Deaths Patients Deaths
 200–349 cells/μL 515 (22) 44 (23) 914 (26) 14 (12)
 ≥350cells/μL 1386 (58) 67 (34) 894 (26) 7 (6)
 Missing 87 (4) 13 (7) 388 (11) 15 (13)
HIV RNA at entry (copies/mL) n (%)
 Median (LQ-UQ) 400 (400–12 900) 400 (400–13100)
 ≤400 copies/mL 1270 (53) 81 (42) 1155 (33) 17 (15)
 >400 copies/mL 1008 (42) 100 (51) 641 (18) 27 (24)
 Missing 106 (4) 14 (7) 1702 (49) 69 (61)
Regimen at entry* [n (%)]
 1st 1335 (56) 81 (42) 2737 (78) 93 (82)
 2nd 438 (18) 39 (20) 522 (15) 12 (11)
 3rd 270 (11) 22 (11) 164 (5) 6 (5)
 4th or more 341 (14) 53 (27) 75 (2) 2 (2)
Median CPE over study (IQR) 8 (7–9) 8 (7–9)
Prior treatment [n (%)]
 Naïve 677 (28) 51 (26) 1082 (31) 51 (45)
 cART and not neurocART 687 (29) 59 (30) 681 (19) 14 (12)
 NeurocART 1020 (43) 85 (44) 1735 (50) 48 (42)
First cART was neurocART [n (%)]
 No 1255 (53) 123 (63) 868 (25) 29 (26)
 Yes 1129 (47) 72 (37) 2630 (75) 84 (74)
Duration of prior neurocART at entry (months)
 Mean (SD) 13 (20.7) 10 (15.4)
Duration of prior cART (not neurocART) at entry (months)
 Mean (SD) 13 (17.1) 4 (11.3)
Complete follow-up (%) 79 86
cART, combination antiretroviral therapy; CPE, central nervous system penetration-effectiveness; HAD, HIV-associated dementia; HBV, hepatitis
B virus; HCV, hepatitis C virus; HET, heterosexual; IDU, injecting drug use; IQR, interquartile range; LQ, lower quartile; MSM, men having sex
with men; neurocART, cART with high CPE rank; SD, standard deviation; UQ, upper quartile.
*
'1st' regimen at entry includes continuing patients and commencing naïive patients.
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Table 3
Sensitivity analyses
Model* HR (neurocART use) 95% CI P>z
New baseline if change in cART changes neurocART status 0.88 (0.68, 1.13) 0.31
Include 'off cART' status 0.95 (0.75, 1.20) 0.65
Deaths following treatment cessation are not counted 0.85 (0.66, 1.09) 0.20
Omit all mono/dual exposures 0.89 (0.69, 1.15) 0.38
Exclude regimens with missing baseline CD4 cell count or viral load 0.84 (0.61, 1.16) 0.29
Poisson model (standard errors adjusted for intra-group correlation) 0.87 (0.67, 1.12) 0.28
cART, combination antiretroviral therapy; CI, confidence interval; HR, hazard ratio; neurocART, cART with high central nervous system
penetration-effectiveness rank.
*
Models were adjusted for age, mode of exposure, hepatitis B virus coinfection, AIDS-defining illness, CD4 cell count and regimen count,
stratified by cohort.
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Table 4
Secondary analyses
Model HR (neurocART use) 95% CI P>z P*
Cox proportional hazards
 Endpoint: ADI or death† 0.93 (0.71, 1.23) 0.61
 First cART=neurocART† 0.91 (0.70, 1.18) 0.48
CPE (four-point scale)†
 ≤6 1.00 0.71
 7 1.04 (0.68, 1.59) 0.86
 8 0.90 (0.59, 1.37) 0.62
 ≥9 0.88 (0.60, 1.28) 0.50
Prior neurocART duration§
 Never 1.00 0.16
 1–9 months 0.89 (0.63, 1.26) 0.52
 10–18 months 1.23 (0.84, 1.80) 0.28
 ≥ 19 months 0.82 (0.60, 1.11) 0.19
GEE – linear § Coef.
CD4 dependent variable 1.01 (0.98, 1.04) 0.52
cART, combination antiretroviral therapy; CI, confidence interval; CPE, central nervous system penetration-effectiveness; GEE, generalized
estimating equation; HR, hazard ratio; neurocART, cART with high central nervous system penetration-effectiveness rank.
*
Wald test for homogeneity for categorical covariates.
†
Model adjusted for age, mode of exposure, hepatitis B virus (HBV) coinfection, AIDS-defining illness (ADI), CD4 cell count and regimen count,
stratified by cohort.
§
Model adjusted for age, mode of exposure, HBV coinfection, ADI and CD4 cell count, stratified by cohort; Akaike information criterion: 4183.7.
§
Model adjusted for age, sex, mode of exposure, HBV coinfection, hepatitis C virus (HCV) coinfection, ADI, CD4 baseline cell count, regimen
count, year of cART commencement, months of cART and cohort.
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